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Oral Contraceptives and Reproductive Cancers: 
Weighing the Risks and Benefits 
By Ann L. Coker, Susan Harlap and Judith A. Fortney 
The hypothetical incidence of reproductive cancers resulting from oral contraceptive use was 
estimated inseveral models comparing the cumulative lifetime incidence of cancer of the breast, 
cervix, ovary and endometrium expected in pill users with the incidence expected in nonusers. 
The potential number of cancer-free days that would be gained or lost by pill users was com- 
pared with similar estimates among nonusers. If five years or more of pill use were associated 
with a 20% increase in the risk of breast cancerbeing diagnosed before age 50, a 20% increase 
in cervical cancer isk and a 50% reduction i the risks of ovarian and endometrial c ncers, then 
every 100,000 pill users would experience 44 fewer eproductive cancers during their lifetime 
than would nonusers, and would gain one more day free of cancer. If higher estimates of the 
five-yearpill-associated risks of breast and cervical cancer are used-a 50% increased risk of 
each, for example-then pill users would experience more reproductive cancers than onusers 
and would have 11 fewer cancer-free days of life. (Family Planning Perspectives, 25:17,1993) 
O ral contraceptives are asafe and ef- 
fective contraceptive method, with 
many beneficial effects on health.' 
Although the majority of studies have 
found no association between breast can- 
cer and oral contraceptive use,2 several re- 
cent reports have suggested that this can- 
cer is diagnosed more frequently inyoung 
women who have used oral contracep- 
tives.3 The existence of a causal relation- 
ship between pill use and breast cancer 
would raise questions about the benefit- 
risk equation for pill use. 
Oral contraceptives are known to pro- 
tect against endometrial cancer4 and ovar- 
ian cancer,5 and this protection isbelieved 
to be causal. In some studies, oral contra- 
ceptives have been associated with an in- 
creased risk of cervical cancer,6 but one re- 
cent report suggests that this association 
is not causal.7 We have created models to 
compare the risk of reproductive cancer 
among women choosing and not choosing 
to use oral contraceptives. This analysis 
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aims to determine whether, given current 
knowledge, pill use would be expected to 
result in a net increase or reduction in the 
risk of reproductive cancer. 
Our approach uses decision analysis, a
tool that is increasingly being used not only 
in clinical practice but also in public health 
policy.8 Methods of decision analysis lead 
to numerical "what if?" calculations that 
allow the comparison of the projected out- 
comes and values of a particular decision. 
In our decision analysis, the decision is 
about whether to use oral contraceptives. 
Although the outcome for an individual 
woman can never be known in advance, 
the probability of different outcomes can 
be estimated before the decision regarding 
whether to use oral contraceptives is made. 
Probabilities, however, "are inexact, be- 
cause they are usually based on a best guess 
or on a synthesis of sometimes conflicting 
results of published studies. Decision analy- 
sis allows the calculation and recalculation 
of these stimated probabilities under vary- 
ing assumptions-known as sensitivity 
analysis. In addition, we can weight dif- 
ferent outcomes according to their desir- 
ability-assigning different "utilities" (i.e., 
weights) to each of the reproductive can- 
cers. In this article, we assign such weights 
based on the probability of surviving five 
years after diagnosis with each cancer. 
Subjects and Methods 
Three comparisons were made in this de- 
cision analysis: The risk of reproductive 
cancer incidence among oral contracep- 
tive users was compared with that among 
nonusers; the potential number of cancer- 
free years gained or lost for pill users was 
compared with that among nonusers; and 
the relative benefit or risk (using a deci- 
sion-analysis tree) to oral contraceptive 
users was compared with that among non- 
users, after taking into account five-year 
survival probabilities. 
In this analysis, women who had used 
the pill for at least five years were compared 
with those not using oral contraceptives for 
this length of time. The comparison category 
therefore includes women who used oral 
contraceptives for less than five years, as 
well as women who used an IUD or a bar- 
rier method and those who had never used 
any contraceptive method. Clearly, the risk 
of reproductive cancer varies according to 
the use of these other contraceptive meth- 
ods. For example, users of barrier methods 
are less likely than other women to devel- 
op cervical cancer. To simplify the analysis, 
however, we compare oral contraceptive 
users with "nonusers," recognizing that he 
nonusers are a heterogeneous group with 
respect o their contraceptive use. 
To conduct this analysis, we required 
data on the incidence of cancer, by site and 
age, the prevalence of pill use by age, and 
estimated relative risks for the relationship 
between oral contraceptive use and each 
cancer. We obtained incidence rates for 
ovarian, endometrial, cervical and breast 
cancer, in five-year age-groups, from the 
1981-1985 U. S. Surveillance, Epidemiol- 
ogy and End Results (SEER) Program.9 We 
used data reported in the 1982 National 
Survey of Family Growth for the preva- 
lence of pill use at each age.10 For the ef- 
fects of oral contraceptives on ovarian and 
endometrial cancer, we took summary es- 
timated relative risks presented in two 
previous analyses.11 
Table 1 (page 18) shows the most prob- 
able relative risks for oral contraceptive use 
and each of the four types of reproductive 
cancer, by age-group. We selected these es- 
timates after eviewing the current litera- 
ture describing the relationship between 
each cancer and pill use. A recent meta- 
analysis of studies on oral contraceptive 
use and breast cancer reported an esti- 
mated relative risk of 1.22 for pill use of 
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Table 1. Estimated relative risks of reproduc- 
tive cancer for oral contraceptive use of five 
years or more, by type of cancer, according to 
age-group 
Cancer type Age-group 
15-49 50-59 ?60 
Breast 1.20 1.00 1.00 
Cervical 1.20 1.00 1.00 
Ovarian 0.50 0.75 1.00 
Endometrial 0.50 0.75 1.00 
more than 10 years among women fol- 
lowed after 1980.12 For a conservative s- 
timate, we have used a relative risk of 1.2 
for pill use of five or more years among 
women younger than 50 and a relative 
risk of 1.0 for women aged 50 and older. 
Similarly, to estimate the rate of cervical 
cancer among oral contraceptive users 
younger than 50, we applied a relative risk 
estimate of 1.2 to the crude incidence rate 
for cervical cancer,13 and a relative risk of 
1.0 for women older than 50. A relative risk 
of 0.5 was applied to estimate pill users' 
risk of ovarian and endometrial cancer 
among those younger than 50,14 a relative 
risk of 0.75 was applied to women aged 
50-59 and one of 1.0 was applied to wom- 
en aged 60 or older. 
Cancer Incidence in Users and Nonusers 
Each comparison in our analyses requires 
an estimate of the cancer incidence among 
pill users and nonusers. To calculate these 
user-specific cancer rates, we applied the 
relative risk for pill use and each cancer 
to the age-specific ancer incidence rates 
obtained from SEER registry data. To cal- 
culate the number of women at risk of a 
specific ancer, we also needed the preva- 
lence of oral contraceptive use of five years 
or more in duration, by age. We were able 
to calculate the number of pill users at risk 
of pill-related cancer using the U. S. age- 
specific population of women and the age- 
specific prevalence of oral contraceptive 
use of five years or more. 
The number of pill users actually de- 
veloping cancer was calculated using the 
age-specific cancer incidence, the relative 
risk estimates for the pill-cancer elation- 
ship and the number of women at risk (i.e., 
who had used the pill for five years or 
more). The cancer rates were calculated by 
dividing the number of oral contraceptive 
users with cancer by the overall number 
of pill users. (The formulas we used in 
these calculations appear in the appendix.) 
For each type of cancer, we used the 
prevalence of pill use by age-group in con- 
junction with the relative risk for oral con- 
traceptives' effect on the specific ancer in- 
cidence to compute the cancer-specific 
incidence rates (per 100,000) for pill users 
and nonusers. We then computed cumu- 
lative rates by taking the sum of the five- 
year age-specific ancer incidence rates 
over the lifetime (through 85 or more 
years) and multiplying the sum by five, 
for the five-year age-groups. 
The cancer incidence rates used for this 
analysis are those reported for all races. Al- 
though cancer incidence rates do vary by 
race, we chose to simplify our analysis by 
using aggregate or summary cancer inci- 
dence rates for U. S. women of all races. 
Since it is not certain that the relationship 
between pill use and each cancer is mod- 
ified by race, we feel that this approach 
provides a reliable comparison of the risks 
and benefits of pill use on the incidence of 
reproductive cancers for all women. 
Excess Risk Among Users and Nonusers 
The difference inthe cancer incidence rates 
between users and nonusers (for each can- 
cer and for all reproductive cancers com- 
bined) is the number of additional cancer 
cases per 100,000 users. The difference in 
risk can be interpreted as the added or re- 
duced risk associated with pill use. This 
index provides an indicator of the mag- 
nitude of the risk or benefit in cancer in- 
cidence associated with pill use. 
Cancer incidence alone was considered 
in these models. Risks from competing 
health problems were not considered, be- 
cause reproductive cancer incidence, even 
considered as one outcome, is still rare; 
therefore, the exclusion of competing risks 
should not affect our selected cancer in- 
cidence outcomes. Further, no long-term 
effect of pill use on cardiovascular disease, 
the outcome most strongly associated 
with the pill, has been reported."5 
Potential Years of Cancer-Free Life Lost 
Our calculation of the potential years of 
cancer-free life lost is almost identical to the 
method used by the Centers for Disease 
Control and Prevention for calculating per- 
son-years of life lost.16 The difference is that 
our outcome is cancer incidence, not the in- 
cidence of cancer death. To compute the 
potential years of cancer-free life lost, we 
multiplied (separately for each user or non- 
user group) the five-year age-specific and 
cancer-specific incidence rates by the dif- 
ference in the mean age at cancer onset 
among the nonusers and by the midpoint 
of the age interval. 
These products were calculated for all 
age intervals up to the interval including 
the mean age of cancer onset. Since the 
mean age at onset varies by cancer site, we 
performed these calculations eparately 
by cancer site, and summed them to yield 
the potential years of cancer-free life lost 
for all reproductive cancers combined. We 
did these calculations eparately for oral 
contraceptive users and nonusers, apply- 
ing to both groups the mean age of can- 
cer onset for nonusers. We then took the 
difference inpotential years of cancer-free 
life lost between the two user groups, 
which indicated the number of years (or 
days) of cancer-free life lost or gained be- 
cause of pill use. 
Decision Tree 
In the decision tree used in this analysis, 
there are two choices-to use oral contra- 
ceptives for five or more years, or not to 
do so. Whether women in need of con- 
traception elect to use or not to use oral 
contraceptives, each has five possible out- 
comes: one of the four reproductive can- 
cers, or no cancer.* The tree compares the 
risk of reproductive cancer separately for 
pill users and for nonusers. 
We multiplied the cumulative lifetime 
incidence of each cancer by two sets of 
weighting factors, for both users and non- 
users. The first set is based on the five-year 
survival probabilities for each cancer- 
85% for endometrial cancer, 76% for breast 
cancer, 67% for cervical cancer and 38% for 
ovarian cancer.17 The second set is based 
on a ranking of the types of cancer in terms 
of their "desirability." In this measure, 
having no reproductive cancer was 
ranked as 1.0, while the types of cancer 
were ranked as follows: 0.8 for endome- 
trial cancer, 0.6 for cervical cancer, 0.4 for 
breast cancer and 0.2 for ovarian cancer. 
We compared the two branches of the 
decision tree by calculating the cancer- 
specific products of the cumulative inci- 
dence and the corresponding set of 
weights. By convention, this summed 
product is termed the "expected value." 
The larger the expected value, the more 
favored the decision. 
Sensitivity Analysis 
The assumptions regarding the strength 
of the relative risk estimates that charac- 
terize the relationship between repro- 
ductive cancer and oral contraceptive use 
are currently subject o much debate; thus, 
we chose to conduct a sensitivity analy- 
sis, in which several relative risk estimates 
for the relationship between pill use and 
breast and cervical cancer could be ap- 
*To simplify the analysis, we ignored the possibility of 
more than one cancer occurring in the same woman, so 
the probability of remaining free of cancer is one minus 
the sum of the probabilities of the four cancers. 
18 Family Planning Perspectives 
plied. (The estimated relative risks for 
ovarian and endometrial cancer associat- 
ed with pill use did not change.) 
When conducting this sensitivity analy- 
sis, we used three relative risk estimates 
other than those we considered most 
probable for the relationship between pill 
use and breast cancer. A relative risk of 1.5 
corresponded to that reported in a meta- 
analysis for pill use of 10 years or more 
among premenopausal women;18 a rela- 
tive risk of 1.1 used for women of all ages 
corresponded with that reported by the 
World Health Organization (WHO) in a 
large, multisite, hospital-based case-con- 
trol study;19 and a relative risk of 1.0 in- 
dicated no increased risk of breast cancer 
associated with pill use. 
The relative risk estimate of 1.2 for oral 
contraceptive use and cervical cancer was 
selected as a best guess for this relation- 
ship, given the controversy surrounding 
whether pill use is causally associated 
with cervical cancer. We also applied the 
following relative risk estimates for the re- 
lationship between pill use and cervical 
cancer: A relative risk of 1.5 correspond- 
ed to that reported in one study of ever- 
users of the pill,20 while a relative risk of 
1.0 corresponded with reports uggesting 
no causal relationship between pill use 
and cervical cancer.21 
Results 
Table 2 presents the difference inrisk of de- 
veloping a reproductive cancer over a 
woman's lifetime (up to age 85 or older) 
associated with pill use of five years or 
more, compared with nonuse. Under the 
assumptions regarding the size and nature 
of the estimated relative risk presented in 
Table 1, pill users would experience 44 
fewer diagnoses of cancer per 100,000 users 
than would nonusers. Across their lifetime, 
pill users would experience 374 addition- 
al breast cancers per 100,000 users and 67 
additional cervical cancers per 100,000, 
compared with nonusers. Pill users would, 
however, experience 215 fewer ovarian 
cancers and 270 fewer endometrial cancers 
per 100,000 than would nonusers. 
Table 2 also presents the period of can- 
cer-free life gained or lost among pill users, 
relative to nonusers. (Cancer-free life mea- 
sures the time until cancer develops, not 
the time until death.) As this table clearly 
shows, the difference inthe period of can- 
cer-free life lost or gained among pill users 
and nonusers is so small that it can be mea- 
sured only in days. Overall, a pill user 
would gain one day free, on average, from 
all types of reproductive cancer considered. 
Users would lose seven days free of breast 
Table 2. Excess reproductive cancers per 
100,000 oral contraceptive users, compared 
with nonusers, and number of cancer-free 
days lost or gained, by type of cancer 
Cancer type Excess cancers Cancer-free 
days 
Total -44 +1 
Breast +374 -7 
Cervical +67 -1 
Ovarian -215 +4 
Endometrial -270 +5 
cancer, compared with nonusers, and per- 
haps one day free of cervical cancer. Pill 
users would gain four days free of ovari- 
an cancer and five days free of endometrial 
cancer, compared with nonusers. 
The decision to use the pill would be 
slightly preferred tothe decision not to use 
it. The expected value for pill use calcu- 
lated using the decision tree and the five- 
year survival probabilities a weights (.943) 
was virtually the same as that for nonuse 
(.942). Expected values calculated using 
the same decision tree but using weights 
based on the desirability ranking show that 
for pill use and nonuse, the four cancer 
outcomes were equal (0.882), indicating no 
difference inthe choice of use or nonuse. 
Table 3 presents sensitivity analyses 
showing how these results change when 
different sets of assumptions are made 
about the effect of pill use on the relative 
risk for breast and cervical cancer, the two 
reproductive cancers for which the size of 
the pill-associated risk remains controver- 
sial. Three sets of assumptions regarding 
the relative risk estimates for pill use and 
breast cancer were applied: a 20% increase 
in breast cancer risk among women aged 
15-49, a50% increase in risk among women 
aced 15-49 and a 10% 
increase for women 
throughout their life- 
time. For each of these 
three groupings, we also 
present findings for 
three different assump- 
tions regarding the cer- 
vical cancer risk associ- 
ated with pill use: a 50% 
increase among women 
aged 15-49, a 20% in- 
crease among women 
aged 15-49 and no in- 
creased risk for women 
of any age. The estimat- 
ed relative risks for pill 
use and endometrial 
and ovarian cancer (0.5) 
were held constant. 
If oral contraceptive 
use of five years or more 
were to cause a 20% increase in breast can- 
cer, a 50% increase in cervical cancer, and 
a 50% decrease in both endometrial and 
ovarian cancers (Table 3, line 1), users 
would experience 177 additional repro- 
ductive cancers per 100,000 users by age 
50, but over their lifetime they would ex- 
perience only 48 additional cancers per 
100,000 users. Pill users would lose one 
cancer-free day, compared with nonusers. 
Using both sets of weights (those based on 
survival probabilities and on the cancer 
outcome rankings), the decision to use oral 
contraceptives would be as favored as the 
decision not to use them (expectancy val- 
ues for survival of .942 and .942, respec- 
tively, and expectancy values for desir- 
ability of .882 and .882). 
Changing the relative risk estimate for 
pill use and cervical cancer to 1.2 (i.e., a 
20% increased risk) would result in pill 
users potentially experiencing 86 more 
cancers per 100,000 by age 50, but 44 fewer 
over their entire lifetime. Users would 
gain one cancer-free day, and the decision 
to use the pill would be equally favored, 
compared with nonuse. 
Finally, if pill use were not associated 
with cervical cancer, pill users would ex- 
perience 19 additional reproductive can- 
cers per 100,000 by age 50, but experience 
111 fewer cancers over their entire lifetime. 
Pill users would gain two cancer-free 
days, and the decision to use the pill 
would be equally favored (Table 3, line 3). 
If we assume that oral contraceptive use 
is associated with a 50% increase in breast 
cancer (an illustration of a worst-case sce- 
nario, based on the 1990 meta-analysis22), 
pill users would experience a range of 
528-687 additional reproductive cancers 
Table 3. Excess cancers among women younger than 50 and 
throughout heir lifetime; number of cancer-free days lost or 
gained; and expected values for use and for nonuse of oral con- 
tiVaceptives, by survival and desirability ranking; all according to 
excess breast and cervical cancer risk associated with oral con- 
traceptive use of five years or more 
% excess Excess cancers Cancer- Expected values 
cancer risk* per 100,000 users free days (use/nonuse) based on: 
<50 Lifetime Survival Desirability 
Breast-20% 
Cervical-50% 177 48 -1 .942/.942 .882/.882 
Cervical-20% 86 -44 +1 .943/.942 .882/.882 
Cervical-0% 19 -111 +2 .943/.942 .882/.882 
Breast-50% 
Cervical-50% 687 558 -11 .941/.942 .879/.883 
Cervical-20% 596 476 -9 .942/.942 .879/.883 
Cervical-0% 528 400 -8 .942/.942 .880/.883 
Breast-1 0% 
Cervical-50% 90 1,156 0 .940/.942 .875/.882 
Cervical-20% -2 1,065 +1 .940/.942 .875/.882 
Cervical-0% -69 998 +2 .940/.942 .875/.882 
In all scenarios, the risks for ovarian and endometrial c ncer are assumed to be 50% (i.e., a 
50% reduction). 
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per 100,000 by age 50, depending upon the 
assumed level of pill-associated cervical 
cancer isk, and 400-558 additional cancers 
per 100,000 across their lifetime. Compared 
with nonusers, pill users would lose 8-11 
cancer-free days during their lifetime. The 
decision to use the pill would be equally 
favored, relative to nonuse, when survival 
probabilities are used as weights, while the 
desirability weights would slightly favor 
the decision not to use the pill. 
Whether oral contraceptives are asso- 
ciated with an excess breast cancer risk in 
women older than 50 remains unclear. To 
assess the cancer impact should any pos- 
sible increase in breast cancer risk be not 
exclusive to women's reproductive years, 
we also present analyses that assume oral 
contraceptive use is associated with a 10% 
excess risk of breast cancer across all ages. 
In such a case, users would experience 
anywhere from 90 more to 69 fewer re- 
productive cancers by age 50, depending 
on the pill-related effect on cervical can- 
cer risk. However, users would experience 
998-1,156 more cancers per 100,000 dur- 
ing their lifetime, depending on the as- 
sumed pill-cervical cancer relationship. 
Users would gain only 1-2 cancer-free 
days. Based on both sets of weights, the 
decision not to use oral contraceptives 
would be favored (Table 3). 
Discussion 
Estimated models of the hypothetical in- 
cidence of reproductive cancers indicate 
that, at least in terms of cancer incidence, 
oral contraceptives are a safe option for 
birth control, even after taking into ac- 
count current concerns over whether 
young pill users are more likely to be di- 
agnosed with breast and cervical cancer, 
As the sensitivity analysis (Table 3) il- 
lustrates, the decision whether to use oral 
contraceptives, based on cancer risk alone, 
depends on the assumptions one makes 
about the relationship between pill use and 
breast cancer. We chose to begin our deci- 
sion analysis using the relative risk for oral 
contraceptive use and breast cancer esti- 
mated in a 1990 meta-analysis,23 since this 
might be viewed as the best current esti- 
mate. Based on this relative risk estimate 
of 1.2 among women younger than 50, the 
decision to use the pill is a better choice 
than nonuse, because fewer users would 
develop cancer during their lifetime. 
Whether pill use increases the risk of 
cervical cancer is as controversial as 
whether oral contraceptives increase the 
risk of breast cancer. Therefore, inthe sen- 
sitivity analysis, different relative risks for 
both breast and cervical cancer were used. 
We chose to present results based on the 
controversial report from a hospital-based 
case-control study as a presentation of a 
worst-case scenario.24 (As was noted in a 
subsequent publication,25 the choice of a 
hospital-based control group may have 
exaggerated the relative risk estimate, 
since hospitalized women may have con- 
ditions that contraindicate pill use.) There- 
fore, the estimates resulting from the sen- 
sitivity analysis using a 50% increased risk 
of breast cancer among younger women 
should be considered the most extreme s- 
timate of risk associated with pill use, and 
perhaps an overestimate. 
Finally, we used the relative risk esti- 
mate, reported by the WHO, of 1.1 for oral 
contraceptive use and breast cancer among 
women of all ages because the results were 
based on a recent and relatively large, well- 
designed hospital-based case-control 
study.26 Given that studies allowing a suf- 
ficient latency period for pill-associated 
cancer development in older women have 
not been possible, we can only conjecture 
the true effect of pill use on breast cancer 
risk among women older than 50. 
We applied a relative risk estimate of 1.1 
to estimate the risk-benefit relationship for 
oral contraceptives onreproductive cancer 
if the pill did increase the risk of breast can- 
cer beyond the reproductive years. Under 
those circumstances, ach 100,000 pill users 
would experience a range of 998-1,156 more 
reproductive cancers than nonusers, de- 
pending on the relative risk for cervical can- 
cer used. The reason for the increased num- 
ber of reproductive cancers among pill users 
when the relative risk of 1.1 is applied to 
women of all ages is that the majority of 
breast cancer cases occur among women 
older than 50. Under the same assumptions, 
pill users would gain up to two cancer-free 
days relative to nonusers. Since the major- 
ity of breast and endometrial cancer cases 
occur after age 50 and the estimate of po- 
tential cancer-free time lost more heavily 
weights time lost before age 65, pill users 
fare better than nonusers only in terms of 
cancer-free time lost. 
One limitation of this analysis is our 
simple but straightforward approach of 
comparing longer term pill users with all 
other women. Clearly, these nonusers are 
not a homogeneous group of women who 
have never used any contraceptive meth- 
od; they include women who used the pill 
f'or fewer t:han five years, women who 
used IUDs, barrier methods, other less re- 
liable methods or a combination of these 
methods, and women who never prac- 
ticed contraception. We chose this het- 
erogeneous comparison group for sever- 
al reasons: First, in many ways it is similar 
to the types of comparison groups used 
in the majority of studies of pill use and 
cancer;* second, it is a comparison more 
easily understood by consumers. 
Our analysis considers only reproduc- 
tive cancer. Pill use has many other health 
effects, including a reduction in the risk 
of iron deficiency anemia, ovarian cysts, 
uterine fibroids, benign breast disease, 
pelvic inflammatory disease and ectopic 
pregnancy,27 as well as an increased risk 
of cardiovascular disease, primarily 
among women who smoke or those with 
other cardiovascular isk factors.28 
This analysis did not consider the po- 
tential synergistic effects of other risk fac- 
tors (e.g., family history of cancer or pari- 
ty) on the relationship between pill use and 
the risk of reproductive cancer. It remains 
unclear whether such effects exist. Prelim- 
inary studies suggest no synergism be- 
tween pill use and family history on the risk 
of breast cancer.29 To be cautious, howev- 
er, women at high risk of reproductive can- 
cer should not use these models to weigh 
their risk of cancer, because the estimates 
presented are based on the risk associated 
with the average population of women- 
who are at a relatively lower risk of cancer. 
Several authors have systematically 
contrasted risks and benefits of oral con- 
traceptive use on health.30 Because it in- 
cludes in their risk-benefits models the 
finding that breast cancer is diagnosed 
more frequently among pill users younger 
than 45, recent work by Diana Petitti and 
Deborah Porterfield3l and by Martin 
Vessey32 is most comparable to our risk- 
benefit analyses. Petitti and Porterfield es- 
timated the lifetime probability of devel- 
oping any reproductive cancer for three 
regions with different cancer patterns 
(Western Europe, Asia and Central and 
South America), under three sets of as- 
sumptions regarding the size and nature 
of the relative risk estimate for pill use 
and cancer. Although they chose slight- 
ly different relative risk estimates for pill 
use and cancer, as well as a different out- 
come measure (lifetime probability of can- 
cer development), their results and con- 
clusions were similar to ours. Under a 
likely case assumption regarding pill use 
and cancer risk, they found that pill users, 
compared with nonusers, would increase 
only slightly their lifetime probability of 
any reproductive cancer. 
*It is true that these studies do not include pill use of less 
than five years' duration with nonuse, but we believe that 
pill use of more than five years best distinguishes longer 
term users, who may be the women at most increased 
risk of pill-related cancer (where such risk is relevant). 
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In a more comprehensive assessment of 
the pill-related health risks and benefits- 
estimating the expected mortality differ- 
ence (in terms of numbers of deaths) be- 
tween pill users and nonusers for hepatic, 
endometrial, ovarian, breast and cervical 
cancers, acute myocardial infarction, sub- 
arachnoid hemorrhage, cerebral throm- 
bosis, venous thromboembolism and un- 
planned pregnancy-Vessey concluded 
that unless early use of combined oral con- 
traceptives is found to have an effect on 
breast cancer risk that persists beyond age 
35, the benefits of pill use on the selected 
outcomes exceed the risks. Again, al- 
though Vessey assessed a different out- 
come measure (mortality), looked at a 
wider range of risks and benefits of pill 
use and made slightly different assump- 
tions regarding the relative risk estimates 
for pill use and the selected outcomes, his 
estimates regarding the favorable bene- 
fit-risk balance for continued pill use are 
supported by our results. 
Our analyses indicate that pill use has 
a minimal net effect on reproductive can- 
cer risk. Nonetheless, many American 
women believe oral contraceptive use is 
associated with cancer. In a 1985 Gallup 
poll, 31% of American women said they 
believed that cancer is a major health risk 
associated with using the pill.33 In the 
same poll, 65% of women rated child- 
bearing as less risky than or as risky as pill 
use. If these myths about the risks and 
benefits of oral contraceptive use are to be 
dispelled, women must continue to be 
provided with objective information on 
the risks and benefits of the pill, in a clear 
and understandable format. 
The ultimate choice of whether to use 
the pill rightly rests with the individual 
woman experiencing the risks and bene- 
fits of its use. Our analysis provides a com- 
parison of the risks and benefits of pill use 
in terms of reproductive cancers alone. 
The primary purpose of oral contracep- 
tives, reducing unwanted fertility, was not 
separately considered in this analysis. The 
value placed on effectively controlling 
one's fertility must also be considered 
when a woman chooses whether or not to 
use the pill. 
Appendix 
To calculate cancer incidence rates among 
oral contraceptive users and nonusers at 
each age, we applied the following for- 
mulas for the age-specific ncidence of can- 
cer among all women (I) and the number 
of cancers among nonusers (y): I=(x+y)/ 
(N1 +N2) and y=[(x/N1)/RRI xN2. In these 
equations, x equals the number of cancers 
among pill users, by age-group; N1 equals 
the number of women using the pill, by 
age-group (calculated from the total pop- 
ulation in an age-group multiplied by the 
proportion of pill users in the age-group); 
N2 equals the number of women not using 
the pill (calculated from the total popula- 
tion in an age-group multiplied by one 
minus the proportion of pill users in the 
age-group); and RR equals the age-specific 
estimated relative risk associated with pill 
use for a specific type of cancer. 
The second equation was substituted 
into the first and solved for x to produce 
the following equation: x=I-(N1+N2)/ 
([N2/RRxN1]+1). The cancer incidence 
among pill users could then be calculated 
as x/N1, while the cancer incidence among 
nonusers could be calculated as y/N2. 
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data. Do women rationalize having re- 
ceived inadequate prenatal care by pro- 
viding acceptable responses to questions 
about barriers to care? It is impossible to 
know how often they may do so. 
Nonetheless, the challenge to materni- 
ty care providers and public health pro- 
fessionals is to develop a comprehensive, 
multifaceted approach that addresses the 
numerous and complex structural and 
personal barriers to good prenatal care. If 
the United States is to achieve its objective 
of no more than seven infant deaths per 
1,000 live births by the year 2000,16 a com- 
mitment o long-term solutions that in- 
volve political and social change is es- 
sential. Addressing only the behavioral 
manifestations of our social ills, without 
touching on the causes, maintains the sta- 
tus quo without improving the health and 
well-being of women and children. 
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Correction 
In "The Association of AIDS Educa- 
tion and Sex Education with Sexual 
Behavior and Condom Use Among 
Teenage Men," by Leighton C. Ku, 
Freya L. Sonenstein and Joseph H. 
Pleck [24:100], the minus sign was left 
off the coefficient shown in Table 2 for 
AIDS education and number of part- 
ners. The coefficient should be -.305. 
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